bpc-157 clinical trials fda ind Understanding the Legal Risks of and Other Unapproved Peptides – Holt Law This Week at FDA: HHS

BPC-157: 0.5 mg daily, either as single dose or split 0.25 mg twice daily TB-500: 2-2.5 mg twice weekly (Monday/Thursday) totaling 4-5 mg per week Duration: 4-6 weeks loading phase, then 2-4 weeks maintenance Important: Use separate vials and syringes for each peptide

"Type 2 diabetes, stable, A1C 6.8%" tells auditors exactly what you're managing and at what complexity level

Key Takeaways "Safety" depends on context: Laboratory handling safety, compound purity, and clinical safety profiles are three different questions Purity is the #1 variable: A 98% pure peptide and a 70% pure peptide are not the same product contamination is the primary risk factor Third-party testing is the standard: Vendor-provided COAs are a starting point

They could: cause infection, allergic reactions, possible interactions with other medications an individual might be taking, and other health complications contain high-risk ingredients, additives or contaminants that may or may not be listed on the label not have been manufactured or stored safely

Treatment Comparison

After reconstitution, store refrigerated between 2C and 8C